Known targets — ChEMBL curated mechanism
fasrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmB1rpmB2rpmCrpmDrpmErpmFrpmG1rpmG2rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsR1rpsR2rpsSrpsTrpsZ
The experimentally established mechanism targets of Pyrazinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.71 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.71 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrazinamide SCHEMBL18364989 | 1.00 | — | — | |
| Pyrazinamide SCHEMBL18364990 | 1.00 | — | — | |
| Pyrazinamide SCHEMBL29408106 | 1.00 | — | — | |
| Pyrazinamide SCHEMBL24102 | 1.00 | — | — | |
| Pyrazinamide SCHEMBL18364991 | 1.00 | — | — | |
| Pyrazinamide SCHEMBL29518620 | 1.00 | — | — | |
| Pyrazinamide SCHEMBL6162016 | 0.98 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL5010455 | 0.98 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL11617895 | 0.98 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL32667957 | 0.98 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110441424-A | Method in relation to substance in a kind of liquid chromatography analysis measurement pyrazinamide | JIANGSU FOUR RINGS BIOPHARMACEUTICAL CO LTD | 2019-11-12 | — | — | CN | disclosed |
| CN-109721554-A | A kind of 4- amino-quinazoline compound and its preparation method and application | 贵州大学 | 2019-05-07 | — | — | CN | disclosed |
| EP-3344325-A1 | LOCAL ADMINISTRATION OF DRUGS FOR THE TREATMENT OF ASTHMA | Mercator Medsystems, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| CN-107164350-A | A kind of pyrazinamide hydrolase and its encoding gene and application | 湖北大学 | 2017-09-15 | — | — | CN | disclosed |
| CN-103271083-B | Multi-functional ionic liquid compositions | 阿拉巴马大学 | 2017-08-11 | — | — | CN | disclosed |
| WO-2017040605-A1 | LOCAL ADMINISTRATION OF DRUGS FOR THE TREATMENT OF ASTHMA | MERCATOR MEDSYSTEMS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-3086646-A2 | PLANTS CONTAINING BENEFICIAL ENDOPHYTES | Indigo AG, Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| CN-106061480-A | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2016-10-26 | — | — | CN | disclosed |
| WO-2015100431-A2 | PLANTS CONTAINING BENEFICIAL ENDOPHYTES | SYMBIOTA, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20110217265-A1 | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-08 | — | — | US | disclosed |
| CN-201959275-U | Tablet capsule used for curing tuberculosis | HEILONGJIANG FUHEHUAXING PHARMACEUTICAL GROUP CO LTD | 2011-09-07 | — | — | CN | disclosed |
| CN-102151267-A | Tablet capsule for curing tuberculosis | HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO LTD | 2011-08-17 | — | — | CN | disclosed |
| WO-2010039195-A2 | SCREENING FOR INHIBITORS OF HCV AMPHIPATHIC HELIX (AH) FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
| US-4085211-A | DIURETICS, NATRIURETICS | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217265-A1 | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function | NSF, HAVCR2, ABHD16A | ADORA3 1601/4885TSHR 3280/4885MC4R 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.